What is the Latest US Regulatory Outcome for Diclofenac by Amzell?
The US Food and Drug Administration (FDA) has approved Amzell's diclofenac sodium delayed-release tablets. This approval marks a significant regulatory milestone for the company regarding this medication [1].
When is Exclusivity for Diclofenac Expected to End?
Information regarding the specific exclusivity end date for Amzell's diclofenac sodium delayed-release tablets is available through patent and exclusivity tracking resources. DrugPatentWatch.com provides detailed data on patent expiries and market exclusivity for pharmaceuticals [2].
What are the Potential Applications of Diclofenac?
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with various conditions. It is commonly prescribed for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis [3].
Are There Other Formulations or Manufacturers of Diclofenac Available?
Diclofenac is available in multiple dosage forms and is manufactured by various pharmaceutical companies. These include oral tablets, extended-release tablets, topical gels, and patches. The specific formulation approved for Amzell is delayed-release tablets [1, 3].
What are the Risks Associated with Diclofenac Use?
Like other NSAIDs, diclofenac carries potential risks. These can include gastrointestinal issues such as ulcers and bleeding, cardiovascular events like heart attack and stroke, and kidney problems. Patients should discuss these risks with their healthcare providers [3].
Where Can I Find More Information on Diclofenac Patents?
Detailed information on patents and regulatory exclusivity for diclofenac, including data specific to Amzell's product, can be found on specialized patent tracking websites such as DrugPatentWatch.com [2].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/